- Home
- LXEH vs ASBP Comparison
LXEH vs ASBP Comparison
Compare LXEH & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | ASBP |
|---|---|---|
| Founded | 2001 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEH | ASBP |
|---|---|---|
| Price | $0.27 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 2.0M |
| Earning Date | 03-15-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $1.41 |
| 52 Week High | $50.08 | $632.00 |
Technical Indicators
Market Signals| Indicator | LXEH | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 58.82 |
| Support Level | $0.20 | $1.44 |
| Resistance Level | $0.39 | $2.45 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 31.74 | 61.73 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.